Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Perphenazine
Drug ID BADD_D01743
Description An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Indications and Usage For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Marketing Status approved
ATC Code N05AB03
DrugBank ID DB00850
KEGG ID D00503
MeSH ID D010546
PubChem ID 4748
TTD Drug ID D02HED
NDC Product Code 42973-165; 51407-697; 68084-607; 68382-592; 0781-8049; 23155-800; 23155-802; 51407-694; 70518-0710; 70518-2639; 70518-3106; 0904-6599; 63629-2248; 63629-2249; 63629-2250; 70518-0940; 70518-2985; 70518-3257; 70771-1042; 64980-290; 70518-0458; 70518-0731; 70518-1739; 70518-3108; 0591-4103; 0781-8047; 52536-164; 64980-291; 64980-292; 64980-293; 68382-593; 70518-1125; 71205-842; 0591-4102; 0603-5060; 0603-5061; 0904-6600; 52536-168; 63629-2251; 63629-2253; 70518-3121; 71205-843; 23155-801; 52536-162; 52536-170; 68084-602; 70771-1041; 71205-844; 0591-4101; 23155-799; 53808-1124; 70518-3033; 0904-6601; 46204-0003; 51407-696; 63629-2252; 68382-591; 70771-1044; 71205-841; 0603-5062; 0603-5063; 0781-8046; 0781-8048; 0591-4104; 68382-594; 70518-2890; 70771-1043; 65372-1191; 51407-695
UNII FTA7XXY4EZ
Synonyms Perphenazine | Perfenazine | Chlorpiprazine | Trilafon
Chemical Information
Molecular Formula C21H26ClN3OS
CAS Registry Number 58-39-9
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicidal ideation19.12.01.003--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Systemic lupus erythematosus10.04.03.004; 15.06.02.003; 23.03.02.006---
Tachycardia02.03.02.007---
Tardive dyskinesia17.01.02.012---
Throat tightness19.01.02.005; 22.12.03.031---
Thrombocytopenic purpura01.08.01.003; 23.06.01.007---
Tongue discolouration07.14.02.006---
Tongue disorder07.14.01.002---
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.009---
Tongue spasm07.14.02.008---
Torticollis15.05.04.003; 17.01.03.003---
Tremor17.01.06.002--
Trismus15.05.04.004; 17.01.03.004--
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Brain oedema12.01.10.010; 17.07.02.003--
Muscle tightness15.05.03.007---
Musculoskeletal stiffness15.03.05.027---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.001---
Faecaloma07.01.03.004---
Faecalith07.01.03.007---
Urine output increased13.13.03.002---
Libido disorder19.08.03.004; 21.03.02.006---
Lactation disorder18.06.02.003; 21.05.02.004--
Decreased appetite08.01.09.028; 14.03.01.005--
Blood disorder01.05.01.004---
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages